retatrutide clinical trials latest ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial retatrutide clinical trials efficacy (RETA)

MNT had the opportunity to speak with Cheng-Han Chen, MD, a board-certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA, about this study

Serum Dominance: Lightweight, fast-absorbing serums are the preferred format for peptide delivery

There's a way to make berberine even better -- both in terms of potency and reducing its downside of requiring a relatively large 1.5 gram daily doses for maximum effects

Ten deaths (1%) on tirzepatide and 12 (1%) on glargine were adjudicated as undetermined, and thus considered cardiovascular deaths for MACE determination

[PubMed ID: 20805868]

For patients with moderate, severe, and end-stage renal disease, a dosage adjustment is required (see Table 2 )